Beyond Efficacy: Why DMPK and Toxicology Matter Earlier Than You Think

When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely. In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi Suryani Chen, Director of Business Development at Crown Bioscience, to explore where DMPK and toxicology fit into the drug discovery picture and how getting them right can save programs from costly detours.